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Abstract
OBJECTIVES: Residual mitral regurgitation after valve repair worsens patients’ clinical outcome. Postimplant adjustable mitral rings
potentially address this issue, allowing the reshaping of the annulus on the beating heart under echocardiography control. We devel-
oped an original mitral ring allowing valve geometry remodelling after the implantation and designed an animal study to assess device
effectiveness in correcting residual mitral regurgitation.
METHODS: The device consists of two concentric rings: one internal and ﬂexible, sutured to the mitral annulus and a second external
and rigid. A third conic element slides between the two rings, modifying the shape of the ﬂexible ring. This sliding element is remotely
activated with a rotating tool. Animal model: in adult swine, under cardio pulmonary bypass and cardiac arrest, we shortened the
primary chordae of P2 segment to reproduce Type III regurgitation and implanted the active ring. We used intracardiac ultrasound to
assess mitral regurgitation and the efﬁcacy of the active ring to correct it.
RESULTS: Severe mitral regurgitation (3+ and 4+) was induced in eight animals, 54 ± 6 kg in weight. Vena contracta width decreased
from 0.8 ± 0.2 to 0.1 cm; proximal isovelocity surface area radius decreased from 0.8 ± 0.2 to 0.1 cm and effective regurgitant oriﬁce
area decreased from 0.50 ± 0.1 to 0.1 ± 0.1 cm2. Six animals had a reversal of systolic pulmonary ﬂow that normalized following the
activation of the device. All corrections were reversible.
CONCLUSIONS: Postimplant adjustable mitral ring corrects severe mitral regurgitation through the reversible modiﬁcation of the
annulus geometry on the beating heart. It addresses the frequent and morbid issue of recurrent mitral valve regurgitation.
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INTRODUCTION
The annuloplasty ring developed by Carpentier [1] in the late
1960s is one of the key elements of mitral valve repair and, since
its description in 1983, this technique has contributed to the
successful treatment of millions of patients suffering from mitral
regurgitation (MR). Despite the recent development of less-
invasive procedures such as MitraClips [2], surgical repair is still
the gold standard treatment for MR [3]. Because the surgical tech-
nique is technically demanding, residual MR is often detectable at
the end of the procedure and affects the surgeon’s decision to
redo the repair or eventually replace the valve: trivial (1+) and
mild (2+) residual MR are usually tolerated, because the mortality
and morbidity associated with another cardiac arrest seem
to exceed the clinical beneﬁt; moderate (3+) and severe
(4+) residual MR usually led to valve replacement. Every cardiac
surgeon has experienced this stressful situation at least once in his
career, but its incidence is not clearly described in the literature
and depends on aetiology. Some authors reported that, in 5–11%
of cases, the postoperative echocardiography identiﬁes residual
MR that requires immediate surgical intervention [4, 5]. Other
studies reported an incidence of residual MR of 30% in patients
treated for ischaemic MR (IMR) with undersized ring annuloplasty
[6]. The clinical impact of less-than-moderate residual MR after
repair is difﬁcult to quantify as well, and only prospective studies
on large cohorts of patients would allow stratifying the risk in
patients suffering from cardiovascular and other diseases.
However, residual 1+ and 2+ MR are clearly associated with a
higher reoperation rate for recurrent MR [7]. There are several
causes leading to failed repair, however, they usually share the
same pathophysiology: inadequate coaptation of the two leaﬂets
during systole, which means <2 mm of leaﬂet overlap.
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Theoretically, any device allowing leaﬂet coaptation surface in-
crease should decrease residual MR.
Postimplant adjustable mitral rings potentially address the
problem of residual MR after repair, allowing the reshaping of the
annulus on the beating heart, particularly reducing the septo-lateral
diameter under echocardiography guidance. Such devices would
help to improve clinical results and probably avoid reoperation.
We developed an original mitral ring that is able to remodel
valve geometry after its implantation and designed an animal study
to assess device effectiveness in correcting residual MR.
MATERIALS AND METHODS
Device description
The Mitralﬂex ring device (Kephalios SA, Paris, France) consists
of two concentric rings: one internal and ﬂexible, sutured to the
mitral annulus and a second, external and rigid. A third conic
element slides between the two rings, modifying the shape of
the ﬂexible ring. The three components receive a Dacron
coating like the current mitral rings. This sliding element is re-
motely activated with a rotating tool that is eventually positioned
under the skin, the same as a pacemaker. The device is currently
available in sizes 28–34 mm (Fig. 1).
Animal model
‘Animal model’ in adult swine equipped with a central venous line,
arterial line and electro cardiogram, under general anaesthesia, the
heart was exposed through left thoracotomy. A 19F Biomedicus
cannula was inserted into the ascending aorta, and a Smart cannula
was inserted into the right atrium trough the right jugular vein.
Cardio pulmonary bypass (CPB) was started and, once the theoret-
ical full ﬂow was reached, the ascending aorta was cross-clamped
and cardiac arrest was induced, injecting crystalloid cardioplegia
into the ascending aorta. Through left atriotomy, the mitral valve
was exposed. Severe MR was created, shortening the primary
chordae of the P2 segment. The shortening was achieved folding
the chordae with metallic clips (Fig. 2). This procedure reproduces
Type III MR according to Carpentier’s classiﬁcation of MR [8]. The
Mitralﬂex ring was then implanted according to the intertrigonal
distance and using Carpentier’s technique [1] (Fig. 3). Eight 2/0
Ticron sutures were used to ﬁx the ring to the mitral annulus. The
left atrium was closed with running suture, leaving the cable pier-
cing the atrial wall at the level of atriotomy. Cross-clamp was
released and the heart deﬁbrillated, if necessary. After weaning the
CPB, we used intracardiac ultrasound (Acuson Sequoia 256)
inserted into the right atrium to assess iatrogenic MR (starting
point). The third element was then displaced in order to decrease
regurgitation as much as possible, and next, the MR was quantiﬁed
again (ending point). The moving element was then repositioned in
its parking position to verify the reversibility of the correction.
Echocardiographic images were recorded for post-processing. The
animal was sacriﬁced with overdose Pentothal injection. For each
animal, the following echocardiographic parameters were calcu-
lated at the starting and ending points: degree of MR (from 1+ to
4+), vena contracta width, proximal isovelocity surface area (PISA)
radius and effective regurgitant oriﬁce area (EROA) according to the
European Association of Echocardiography recommendations [9].
Study endpoints
Primary endpoints are: (i) assessing the efﬁcacy of the Mitralﬂex
ring to reduce MR of 2+ or plus and (ii) reversibility of the MR
correction. Secondary endpoints are: (iii) feasibility of ring im-
plantation using Carpentier’s technique and (iv) secondary bleed-
ing from the cable piercing the left atrium.
The research protocol has received the approval of the local
Ethic Committee and the Cantonal (Canton de Vaud) Veterinarian
Authority (Authorization no. 1708).
RESULTS
Eight animals, 54 ± 6 kg in weight, successfully underwent the
procedure. The mean CPB time was 75.7 ± 21 min with aorta
Figure 1: The Mitralﬂex without the Dacron coating showing its three com-
ponents: a: the external rigid ring; b: the internal deformable ring to be
sutured to the mitral annulus; c: the sliding element that reshape the inner
ring according to the patient’s need; d: the cable that activates the sliding
element.
Figure 2: Creation of severe mitral regurgitation folding the primary chordae
of P2 segment using metallic clips. The length of the chordae has been
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cross-clamp time of 57.5 ± 14 min. The mitral valve was exposed
and chordae referring to P2 folded using 2–3 metallic clips.
Intertrigonal distance was 28 mm in all animals. A 28-mm
Mitralﬂex ring was implanted using the interrupted suture tech-
nique with the conic element in the parking position. Four rings
had no Dacron coating to visualize the conic element move-
ment, right after the implant. In all animals, the conic element
was displaced and replaced in the parking position before left
atrium closure to check the working principle. The cable pierced
the left atrium at the level of the atriotomy, and two supplemen-
tal 4/0 Prolene stitches were added at the exit level to avoid
bleeding. After removing the aortic cross-clamp, the heart was
deﬁbrillated (2–3 shocks 10J) and CPB successfully weaned in
seven of eight animals under inotropic support (adrenaline
3–10 gamma/min). In one animal, valve analysis was done under
CPB running at 1 l/min and consistent inotropic support (adren-
aline 25 gamma/min).
The postoperative intracardiac echocardiography showed MR
in all animals, and the activation of the device allowed the re-
duction of the MR in all cases (Fig. 4). In all cases, the sliding
element was brought at the P2 level in order to achieve the best
correction of MR. In ﬁve animals, the MR disappeared; in three
animals, it was trivial. Vena contracta width decreased from
0.8 ± 0.2 to 0.1 cm; PISA radius decreased from 0.8 ± 0.2 to 0.1
cm and EROA decreased from 0.50 ± 0.1 to 0.1 ± 0.1 cm2. In two
animals, we were unable to calculate PISA and EOAR due to
technical problems. Two animals had a reversal of systolic
pulmonary ﬂow that normalized following the activation of the
device. All corrections were reversible, causing the reappearance
of MR. In three animals, additional sutures were placed to
control bleeding from the left atrium. Table 1 reports the
detailed results. Animals were sacriﬁced at the end of the
procedure and devices retrieved.
DISCUSSION
‘Mitral repair is better than mitral replacement, whenever it’s pos-
sible’ is one of the rare statements agreed on by both cardiolo-
gists and cardiac surgeons. The advantages of mitral valve repair
(MVR) include a low rate of thromboembolism, resistance to
endocarditis and having no need of long-term anticoagulation
[10]. However, repairing the mitral valve is a technically demand-
ing procedure even for experienced surgeons and it is frustrating
when it culminates in residual regurgitation. These lead to a gen-
erally low rate of repair. In a recent review, only about 44% of
patients in the USA and 46% in Europe who required MV surgery
for MR received MVR [10]. The persistence of trivial or mild (1+ to
2+) MR after the repair is generally tolerated, because an almost
perfect repair is better than a second cardioplegia either to
improve the correction or to change the valve. However, clinical
studies have underlined the negative effect of residual MR on out-
comes, particularly in ischaemic cardiopathy: revascularization
alone did not eliminate the negative long-term effects of mild
MR. Coronary artery bypass surgery patients with uncorrected
mild or moderate MR are at increased risk of death (hazard ratio
1.34) and heart failure hospitalization (hazard ratio 1.34) [7, 11].
Even when the repair is successful with excellent postoperative
results, the progression of the degenerative disease and/or
ischaemic cardiomyopathy are the major determinants of MR re-
currence. In a recent study, Flameng et al. [12] reported that only
50% of the patients remain free from more than trivial mitral in-
competence at 7 years after repair for degenerative disease.
Mitralﬂex ring seems to address the need for devices and/or
techniques able to improve the clinical results of MVR. The
device is implanted using the surgical technique initially
described by Carpentier, with the exception of having a 3-mm
thick cable piercing the left atrium. The Mitralﬂex ring provides
the displacement of the posterior leaﬂet segments, keeping the
anterior in place, because the anterior annulus of the mitral
valve is tightly connected to the aortic valvular ring with ﬁbrous
tissue and is not easily dilated or deformed. Any deformation of
the annulus at this level is difﬁcult to achieve and could induce
aortic regurgitation.
The animal model we proposed is based on historical data and
is meant to reproduce the functional changes in MV movements
observed in IMR due to restricted leaﬂet motion. The papillary
muscles, normally parallel to the left ventricle long axis and per-
pendicular to the leaﬂets efﬁciently balance the forces generated
by ventricular pressure on the leaﬂet surface. Ischaemia or heart
failure causes the myocardial segments underlying the PMs to
Figure 4: Intracadiac echocardiography showing severe MR (right) and its cor-
rection after device activation (left).
Figure 3: The Mitralﬂex ring is implanted using the interrupted suture
technique.
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bulge posteriorly and outward, displacing the PMs, so that they
pull the leaﬂets nonperpendicularly, away from their normal
coaptation [13, 14]. The distance between the papillary muscles
tips and the annulus also increases, drawing the leaﬂets into the
ventricle and restricting their motion towards closure [15, 16].
Because the cable was a source of minor bleeding in three
animals, we recommend placing additional sutures on the left
atrium at the exit site in order to reduce bleeding complication.
Echocardiographic evaluation of the severity of MR is
complex, and simple ‘eyeball’ grading of MR colour ﬂow jets is
prone to error. However, all quantitative measurement methods
such as vena contracta width, regurgitate volume and EROA have
inherent strengths and weakness. Vena contracta width is simple
and good at identifying mild or severe MR, but not useful for
multiple MR jets, and the small values could lead to a large per-
centage of errors. PISA provides both lesion severity (EROA) and
volume overload, but is cumbersome and not accurate in eccen-
tric jets. Moreover, intracardiac ultrasound is not routinely per-
formed and we personally lack experience with this technique.
Therefore, we integrated the various echocardiographic mea-
sures of MR severity, trying to minimize measure errors.
The reshaping of the mitral annulus induced by the activation
of the device allowed the precise correction of 2+ MR in the
postoperative phase. The activation of the ring was smooth,
and under echocardiography control, we were able to reshape
the posterior leaﬂet geometry to optimize leaﬂet coaptation.
Because the correction was very precise and reversible, in all
animals, we were able to adjust leaﬂet coaptation as many times
as necessary to minimize MR, and this is a step forward with
respect to other active mitral rings that provide only one direc-
tion and ﬁxed modiﬁcation of valve geometry [17].
Although this ring has the same clinical indications as the clas-
sical rigid mitral rings, it should provide particular beneﬁt in IMR.
Experimental and clinical studies have demonstrated that patients
with IMR have decreased annular motion during the cardiac cycle
[18] and both anterior and posterior portions of the annulus dilate
proportionately to IMR severity, although the magnitude of the
dilatation of the posterior annulus is greater [19]. Similarly, the
intertrigonal distance is increased in IMR at end diastole, and
these changes are the result of wall motion abnormalities due to
myocardial infarction in the distribution of the dominant right
coronary artery [20]. The altered geometry of the left ventricle
results in the loss of function of the valve secondary to excess
tethering of the valve leaﬂets and resultant loss of zone coapta-
tion. Surgical repair by annuloplasty effectively reduces the
septal–lateral diameter of the mitral annulus [21] and, when acti-
vated, the Mitralﬂex ring further reduces this distance, increasing
the leaﬂets coaptation. It should represent an additional tool to
improve immediate and mild-term correction results of MR.
Because the Mitralﬂex ring is thought to be activated even
months or years after the implant, we could speculate that it
could be helpful to correct recurrent MR and therefore to
improve the clinical outcome of mitral repair, but further studies
are necessary to conﬁrm this statement.
Without adding complexity to the standard surgical procedure
or additional risks for the patient, the Mitralﬂex ring expands the
opportunity to perform effective, good mitral repair and to
correct recurrent mitral regurgitation, probably improving clinical
outcome.
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APPENDIX. CONFERENCE DISCUSSION
Dr A. Ahlsson (Örebro, Sweden): I would like to take the position of an
average mitral valve surgeon trying to understand the place of adjustable
mitral rings in mitral valve repair surgery. The absolute majority of our
patients undergo mitral valve surgery because of type II prolapse of one or
more segments, and a failed mitral valve repair in this group of patients can
rarely be explained by the choice of the annuloplasty ring. Maybe you think
you have pinpointed this, but I would like you once more to state it. Can you
please deﬁne the group of MR patients in whom you think the use of adjust-
able mitral rings will improve long-term outcome?
Dr Tozzi: Initially, we were thinking about patients with functional mitral re-
gurgitation, as for example, in Barlow’s disease. Then we thought that prob-
ably this ring also has a place in the treatment of ischaemic mitral
regurgitation. So basically this ring could be used as an alternative to the
classic Carpentier ring.
Dr Ahlsson: For all patients?
Dr Tozzi: Yes.
Dr Ahlsson: My second question deals with the practical problem of
leaving a rotable tool in the left atrium piercing the atrial wall. I get a little
worried about the risk of thrombosis, emboli or bleeding or if you are in
heavy exercise. I would like your comment on this.
Dr Tozzi: Well, as you saw in the paper, we had two animals that had
bleeding just because it was early in the experience. So we decided to
improve the purse string suture where the cable pierced the atrium. And then
concerning the thrombi, these were all acute animal studies, so we do not
have long-term experience. But we are conﬁdent that if the ring is covered
with biocompatible material as used in standard rings, like Dacron for
example, such complications should be avoided.
Dr A. Diegeler (Bad Neustadt, Germany): In those patients with ischaemic
mitral incompetence, usually the lack of coaptation is located more towards
the postero-medial part. Has the ring any option to address this by a kind
of asymmetric shrinking or does it always provide a symmetric shrinking?
Dr Tozzi: Yes, absolutely. This kind of ring can address the asymmetric dis-
placement of the posterior leaﬂet. So you can choose to reduce the AP dis-
tance at the level of P3, for example, or P2 or P1 according to the need. And
it is extremely selective, so it is not just a general shrinking of the annulus.
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